Eurizon Capital SGR S.p.A. boosted its holdings in shares of Elanco Animal Health Incorporated (NYSE:ELAN – Free Report) by 139.8% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 92,821 shares of the company’s stock after buying an additional 54,111 shares during the quarter. Eurizon Capital SGR S.p.A.’s holdings in Elanco Animal Health were worth $2,080,000 as of its most recent SEC filing.
Several other hedge funds and other institutional investors also recently added to or reduced their stakes in ELAN. Anchor Investment Management LLC acquired a new position in shares of Elanco Animal Health in the second quarter worth $29,000. Covestor Ltd increased its position in shares of Elanco Animal Health by 48.2% during the third quarter. Covestor Ltd now owns 1,383 shares of the company’s stock worth $31,000 after acquiring an additional 450 shares during the period. Integrated Wealth Concepts LLC purchased a new stake in shares of Elanco Animal Health during the second quarter worth $35,000. Fulcrum Asset Management LLP acquired a new stake in shares of Elanco Animal Health in the third quarter valued at $36,000. Finally, Mitsubishi UFJ Asset Management Co. Ltd. acquired a new stake in shares of Elanco Animal Health in the second quarter valued at $38,000. Hedge funds and other institutional investors own 97.48% of the company’s stock.
Elanco Animal Health Price Performance
ELAN stock opened at $26.48 on Tuesday. The business has a 50 day moving average price of $23.42 and a 200 day moving average price of $23.89. The stock has a market cap of $13.23 billion, a price-to-earnings ratio of -88.25, a PEG ratio of 2.24 and a beta of 1.73. Elanco Animal Health Incorporated has a fifty-two week low of $19.40 and a fifty-two week high of $27.98. The company has a quick ratio of 1.10, a current ratio of 2.09 and a debt-to-equity ratio of 0.55.
Elanco Animal Health (NYSE:ELAN – Get Free Report) last announced its quarterly earnings results on Friday, November 6th. The company reported $0.27 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.20 by $0.07. The firm had revenue of $1.26 billion during the quarter, compared to the consensus estimate of $1.21 billion. Elanco Animal Health had a positive return on equity of 8.80% and a negative net margin of 2.86%. The firm’s quarterly revenue was up 11.3% compared to the same quarter last year. During the same period in the prior year, the company posted $0.19 earnings per share. Elanco Animal Health has set its Q4 2026 guidance at 0.160-0.190 EPS and its FY 2026 guidance at 1.170-1.200 EPS. Equities research analysts anticipate that Elanco Animal Health Incorporated will post 1.18 earnings per share for the current fiscal year.
Insider Activity at Elanco Animal Health
In related news, Director Lawrence Kurzius acquired 40,000 shares of Elanco Animal Health stock in a transaction dated Thursday, August 20th. The stock was acquired at an average price of $23.40 per share, for a total transaction of $936,000.00. Following the transaction, the director owned 188,647 shares of the company’s stock, valued at $4,414,339.80. This represents a 26.91% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Timothy Bettington sold 4,350 shares of the company’s stock in a transaction on Thursday, October 15th. The shares were sold at an average price of $23.00, for a total transaction of $100,050.00. Following the completion of the transaction, the insider owned 138,911 shares of the company’s stock, valued at approximately $3,194,953. The trade was a 3.04% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 1.14% of the stock is currently owned by insiders.
Analyst Upgrades and Downgrades
ELAN has been the subject of a number of recent research reports. Weiss Ratings upgraded Elanco Animal Health from a “sell (d)” rating to a “sell (d+)” rating in a report on Friday, September 4th. Jefferies Financial Group cut Elanco Animal Health from a “buy” rating to a “hold” rating and lowered their target price for the stock from $31.00 to $24.00 in a research note on Tuesday, October 20th. KeyCorp restated an “overweight” rating on shares of Elanco Animal Health in a report on Monday, November 9th. Morgan Stanley reduced their price target on Elanco Animal Health from $26.00 to $25.00 and set an “equal weight” rating on the stock in a research report on Thursday, October 29th. Finally, UBS Group lifted their price objective on Elanco Animal Health from $31.00 to $33.00 and gave the company a “buy” rating in a research note on Thursday, August 6th. One research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $29.75.
View Our Latest Stock Report on Elanco Animal Health
Elanco Animal Health Profile
Elanco Animal Health is a global animal health company that develops, manufactures and markets products for companion animals and livestock. Its offerings include medicines, vaccines and other products intended to prevent and treat disease and support animal health. For pets, Elanco provides treatments for conditions including parasitic infections, pain and chronic diseases. Its livestock products support the health of animals such as cattle, poultry, swine and fish, serving producers and veterinarians.
Further Reading
- Five stocks we like better than Elanco Animal Health
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Want to see what other hedge funds are holding ELAN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Elanco Animal Health Incorporated (NYSE:ELAN – Free Report).
Receive News & Ratings for Elanco Animal Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Elanco Animal Health and related companies with MarketBeat.com's FREE daily email newsletter.
